- Home
- VIGL vs STKS Comparison
VIGL vs STKS Comparison
Compare VIGL & STKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- STKS
- Stock Information
- Founded
- VIGL 2020
- STKS 2004
- Country
- VIGL United States
- STKS United States
- Employees
- VIGL N/A
- STKS N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- STKS Restaurants
- Sector
- VIGL Health Care
- STKS Consumer Discretionary
- Exchange
- VIGL Nasdaq
- STKS Nasdaq
- Market Cap
- VIGL 89.3M
- STKS 105.2M
- IPO Year
- VIGL 2022
- STKS N/A
- Fundamental
- Price
- VIGL $3.03
- STKS $3.09
- Analyst Decision
- VIGL Strong Buy
- STKS Buy
- Analyst Count
- VIGL 5
- STKS 3
- Target Price
- VIGL $21.00
- STKS $5.83
- AVG Volume (30 Days)
- VIGL 642.5K
- STKS 81.0K
- Earning Date
- VIGL 03-25-2025
- STKS 03-13-2025
- Dividend Yield
- VIGL N/A
- STKS N/A
- EPS Growth
- VIGL N/A
- STKS N/A
- EPS
- VIGL N/A
- STKS N/A
- Revenue
- VIGL N/A
- STKS $541,400,000.00
- Revenue This Year
- VIGL N/A
- STKS $105.12
- Revenue Next Year
- VIGL N/A
- STKS $26.74
- P/E Ratio
- VIGL N/A
- STKS N/A
- Revenue Growth
- VIGL N/A
- STKS 63.49
- 52 Week Low
- VIGL $1.49
- STKS $2.68
- 52 Week High
- VIGL $6.06
- STKS $6.10
- Technical
- Relative Strength Index (RSI)
- VIGL 77.87
- STKS 39.83
- Support Level
- VIGL $2.71
- STKS $3.13
- Resistance Level
- VIGL $2.95
- STKS $3.41
- Average True Range (ATR)
- VIGL 0.21
- STKS 0.20
- MACD
- VIGL 0.03
- STKS -0.05
- Stochastic Oscillator
- VIGL 86.18
- STKS 24.13
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Kona Grill, ONE Hospitality, and Corporate. The company generates the vast majority of its revenue from the domestic market.